Private equity firm Apollo has agreed to invest €3 billion for a minority stake in a newly created entity housing Bayer's long-acting reversible contraceptives business. The transaction gives Apollo a non-controlling interest in a portfolio that includes established brands such as Mirena and Kyleena, marking one of the largest private equity investments in a European pharmaceutical asset this year.

The structure separates the contraceptives franchise from Bayer's broader pharmaceutical operations, allowing the German conglomerate to monetize a stable cash-generating unit while retaining operational control. Proceeds will bolster Bayer's balance sheet as it navigates increased liquidity requirements tied to litigation settlements and restructuring costs, giving management more financial flexibility without a full divestiture.

For Apollo, the deal fits a pattern of targeting resilient healthcare assets with predictable revenue streams. The contraceptives franchise benefits from high switching costs, strong physician loyalty, and demographic tailwinds in women's health. The investment also signals continued appetite from large alternative asset managers for carve-out transactions in European pharma, where corporates are streamlining portfolios.

The partnership could accelerate growth initiatives for the contraceptives business, including geographic expansion and lifecycle management, while Bayer focuses capital on its core pharmaceutical pipeline and crop science division. Investors should watch whether this structure becomes a template for other European majors seeking to unlock value from non-core franchises without surrendering strategic oversight.